Detecting early-stage breast cancer with GATA3-positive circulating tumor cells

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-09-01 DOI:10.1016/j.tjog.2024.06.005

Chun-Hsin Hsieh , Ya-Herng Chang , Pei-Ying Ling , Ying-Tai Jin , Pei-Hsuan Lo , Hei-Jen Jou

{"title":"Detecting early-stage breast cancer with GATA3-positive circulating tumor cells","authors":"Chun-Hsin Hsieh , Ya-Herng Chang , Pei-Ying Ling , Ying-Tai Jin , Pei-Hsuan Lo , Hei-Jen Jou","doi":"10.1016/j.tjog.2024.06.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>This case demonstrated the possibility of using GATA3-positive circulating tumor cells (CTCs) to detect early-stage breast cancer (BrC).</p></div><div><h3>Case report</h3><p>The 86 years old female patient received a mammographic examination with no evidence of malignancy <del>(</del>Breast Imaging Reporting and Data System, (BI-RADS category 2). However, CTC testing on the same day revealed four GATA3-positive CTCs in 4 ml of peripheral blood. Core needle biopsy was performed in the suspicious area even with no evidence of malignant image on breast ultrasound. Pathologic examination showed invasive carcinoma of no special type of the breast. The patient then received an oncoplastic partial mastectomy of right breast and sentinel lymph node biopsy. The surgical staging was cT1N0M0. Post-operation follow-up examination showed absence of GATA3-positive CTCs and the presence of HER2/ER positive CTCs.</p></div><div><h3>Conclusion</h3><p>The role of GATA3-positive CTCs as a potential biomarker for early-stage BrC should be explored.</p></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1028455924001864/pdfft?md5=da7b913aa1d0d659a0afb76db4e6d529&pid=1-s2.0-S1028455924001864-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1028455924001864","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This case demonstrated the possibility of using GATA3-positive circulating tumor cells (CTCs) to detect early-stage breast cancer (BrC).

Case report

The 86 years old female patient received a mammographic examination with no evidence of malignancy (Breast Imaging Reporting and Data System, (BI-RADS category 2). However, CTC testing on the same day revealed four GATA3-positive CTCs in 4 ml of peripheral blood. Core needle biopsy was performed in the suspicious area even with no evidence of malignant image on breast ultrasound. Pathologic examination showed invasive carcinoma of no special type of the breast. The patient then received an oncoplastic partial mastectomy of right breast and sentinel lymph node biopsy. The surgical staging was cT1N0M0. Post-operation follow-up examination showed absence of GATA3-positive CTCs and the presence of HER2/ER positive CTCs.

Conclusion

The role of GATA3-positive CTCs as a potential biomarker for early-stage BrC should be explored.

查看原文本刊更多论文

利用 GATA3 阳性循环肿瘤细胞检测早期乳腺癌

病例报告这位 86 岁的女性患者接受了乳房 X 线检查，未发现恶性肿瘤迹象（乳腺影像报告和数据系统（BI-RADS）2 类）。然而，当天的 CTC 检测发现 4 毫升外周血中有 4 个 GATA3 阳性的 CTC。尽管乳腺超声检查未发现恶性影像，但还是在可疑区域进行了核心针刺活检。病理检查显示为无特殊类型的乳腺浸润性癌。患者随后接受了右侧乳房肿瘤整形部分切除术和前哨淋巴结活检。手术分期为 cT1N0M0。术后随访检查显示，患者体内没有 GATA3 阳性的 CTCs，但存在 HER2/ER 阳性的 CTCs。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464